Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

INBX

Inhibrx Biosciences Inc

Nov 13 • 03:11PM ET

74.91

+1.59 2.17 %

Healthcare • Biotechnology • USA • NASD

Peers: BPMC ARVN ONC PTCT EXEL PBYI ADAP KPTI IGMS

| Held by: IWM VTI IWN IBB VXF FESM EES IWC VTWO PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-10.99	Insider Own	31.91%	Shs Outstand	14.48M	Perf Week	-7.51%
Market Cap	1.09B	Forward P/E	-	EPS next Y	-9.32	Insider Trans	-7.04%	Shs Float	9.86M	Perf Month	108.43%
Enterprise Value	1.01B	PEG	-	EPS next Q	-1.72	Inst Own	57.63%	Short Float	10.41%	Perf Quarter	221.09%
Income	-163.69M	P/S	775.07	EPS this Y	-107.21%	Inst Trans	-3.01%	Short Ratio	3.15	Perf Half Y	523.21%
Sales	1.40M	P/B	15.82	EPS next Y	-14.78%	ROA	-69.58%	Short Interest	1.03M	Perf YTD	386.43%
Book/sh	4.74	P/C	5.82	EPS next 5Y	-	ROE	-113.71%	52W High	86.64 -13.54%	Perf Year	368.19%
Cash/sh	12.88	P/FCF	-	EPS past 3/5Y	- -	ROIC	-94.52%	52W Low	10.81 593.29%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.79% -	Gross Margin	-99.00%	Volatility	9.32% 12.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	718.09	EPS Y/Y TTM	-	Oper. Margin	-11929.64%	ATR (14)	6.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.98	Sales Y/Y TTM	-	Profit Margin	-11692.43%	RSI (14)	68.32	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.98	EPS Q/Q	-101.44%	SMA20	14.61%	Beta	1.31	Target Price	12.00
Payout	0.00%	Debt/Eq	1.56	Sales Q/Q	1200.00%	SMA50	66.88%	Rel Volume	0.87	Prev Close	73.32
Employees	161	LT Debt/Eq	1.53	Earnings	Aug 13 AMC	SMA200	221.19%	Avg Volume	325.37K	Price	74.91
IPO	May 29, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	32.97% -	Trades		Volume	250,348	Change	2.17%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Initiated	JMP Securities	Mkt Perform

Nov-04-25 04:01PM	Inhibrx Announces Participation in Upcoming Scientific Conferences (PR Newswire)
Oct-24-25 07:40AM	Inhibrx Biosciences stock soars on chondrosarcoma Phase II victory (Clinical Trials Arena) +102.01%
Oct-23-25 04:05PM	Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -10.03%
Oct-22-25 04:01PM	Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts (PR Newswire) -15.99%
Aug-13-25 04:05PM	Inhibrx Reports Second Quarter 2025 Financial Results (PR Newswire) +7.53%
11:11AM	Loading…
Jul-28-25 11:11AM	Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer (Insider Monkey) +6.46%
Jul-17-25 02:05PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily)
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Jul-10-25 02:24PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily)
May-14-25 04:05PM	Inhibrx Reports First Quarter 2025 Financial Results (PR Newswire) +10.89%
Apr-01-25 04:05PM	Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President (PR Newswire)
Mar-17-25 04:05PM	Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results (PR Newswire)
Jan-21-25 05:01PM	Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer (PR Newswire) +5.19%
Jan-13-25 04:15PM	Inhibrx Biosciences Announces Loan Agreement with Oxford Finance (PR Newswire) -6.60%
Nov-14-24 04:24PM	Inhibrx Biosciences Reports Third Quarter 2024 Financial Results (PR Newswire) -7.25%
04:00PM	Loading…
Nov-04-24 04:00PM	Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation (PR Newswire)
Sep-13-24 01:55AM	Director Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX) (GuruFocus.com) +8.82%
Aug-13-24 06:54PM	Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (PR Newswire)
May-24-24 04:00PM	Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi (PR Newswire)
May-10-24 06:36PM	Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off (PR Newswire)

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
VIKING GLOBAL INVESTORS LP	10% Owner	Oct 07 '25	Sale	32.25	350,000	11,287,500	67,018	Oct 09 04:41 PM
Kayyem Jon Faiz	Director	Nov 19 '24	Buy	14.23	69,686	991,416	51,093	Nov 22 04:03 PM
Kayyem Jon Faiz	Director	Nov 20 '24	Buy	14.19	37,500	532,204	69,843	Nov 22 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INBX

Inhibrx Biosciences Inc

Upgrade your FINVIZ experience